Medtronic stock costs too much. Here are two reasons why.One week ago, medical device maker Medtronic (MDT -1.09%) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts' expectations, Medtronic stock traded down on the news.At the time, I said this was the right call because Medtronic's earnings growth simply wasn't strong enough to support the company's rich valuation. On Thursday, Goldman Sachs agreed with me, initiating cov ...

文章核心观点 - 公司宣布其全资间接子公司Medtronic, Inc.已发行了总计28亿欧元的4只高级债券 [1][2] - 债券发行所得将用于公司一般性用途,包括偿还未偿商业票据和其他债务 [2] - 公司是全球领先的医疗技术公司,致力于解决人类最具挑战性的健康问题 [4] 公司概况 - 总部位于爱尔兰都柏林,是全球领先的医疗技术公司 [4] - 拥有95,000多名员工,业务遍及150个国家 [4] - 公司的技术和疗法涵盖70种健康状况,包括心脏设备、手术机器人、胰岛素泵等 [4] - 公司致力于提供创新技术,改善人们的生活质量 [4] 债券发行情况 - 公司全资间接子公司Medtronic, Inc.发行了4只高级债券 [1] - 债券总额为28亿欧元,期限分别为2029年、2036年、2043年和2053年 [1] - 债券由公司和其全资子公司Medtronic Global Holdings S.C.A.提供全额无条件担保 [1] - 本次债券发行预计于2024年6月3日完成,由花旗、摩根大通、美银和瑞穗担任联席簿记管理人 [2][3]

文章核心观点 - 医疗设备制造商Medtronic连续47年提高了股息支付 [1][6][7] - 尽管Medtronic最新季度业绩公布后股价下跌5%,但一些分析师仍看好公司前景 [2][3][4] - Medtronic在创新医疗设备市场拥有强大优势,其MiniMed 780G系统获得FDA批准 [8][9] - Medtronic持续加大研发投入,近期获批多款新产品,预计未来几年收入和利润将保持中单位数增长 [10][11][12] 根据相关目录分别进行总结 公司概况 - Medtronic是一家医疗设备制造商,拥有47年连续增加股息的历史 [1][6][7] - 公司在创新医疗设备领域具有强大优势,擅长获得监管部门的产品批准 [8][9] 财务表现 - 公司最新一季度业绩公布后股价下跌5%,但分析师仍看好公司前景 [2][3][4] - 公司持续加大研发投入,近期获批多款新产品,预计未来几年收入和利润将保持中单位数增长 [10][11] 新产品动态 - Medtronic获批MiniMed 780G系统,可自动监测血糖并给予胰岛素 [8] - 公司还获批新的经导管主动脉瓣置换系统、脊髓刺激器等产品 [10] - 公司还与英伟达合作开发内窥镜AI辅助聚糜产品GI Genius [12]

Medtronic plc (MDT) recently announced late-breaking data from the global Lead Evaluation for Defibrillation and Reliability (“LEADR”) Pivotal trial at Heart Rhythm 2024. The outcome showed that the investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals.The trial findings were simultaneously published in the Heart Rhythm journal. The development is likely to boost Medtronic’s Cardiac Rhythm Management business within the C ...

Key PointsMedtronic had another solid quarter, with FCF expanding to support healthy dividend growth. The guidance is favorable and includes another year of steady, stable growth. Analysts Hold this stock and see it trading near the low end of the expected range with a possible 15% upside. 5 stocks we like better than MedtronicShares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet an ...

Q4's results exhibited consistent organic revenue growth but it got hit by currency fluctuations and strategic divestitures.Medical technology specialist Medtronic (MDT -5.11%) released fourth-quarter and full-year data for fiscal 2024 on Thursday, May 23, that painted a nuanced financial picture.The company reported $8.59 billion in Q4 revenue which was up less than 1% year over year, yet it rose a robust 5.4% growth on an organic basis (growth not attributable to mergers and acquisitions). Medtronic's bus ...

文章核心观点 - 美敦力公司在2024财年第四季度的调整后每股收益为1.46美元,同比下降7.5%,但超出了分析师预期[1] - 2024财年全年调整后每股收益为5.53美元,同比增长4.5%,也超出了分析师预期[3] - 公司在各个业务板块都实现了中单位数以上的有机收入增长[6] 业务板块总结 心血管业务 - 心脏节奏与心力衰竭业务收入同比增长1.3%[8] - 结构性心脏与主动脉业务收入同比下降20.1%[8] - 冠脉与外周血管业务收入同比增长4.6%[8] 医疗外科业务 - 整体收入同比增长3.5%,其中手术与内窥镜业务增长4.1%,急诊护理与监护业务增长1.2%[9] 神经科学业务 - 整体收入同比增长5.6%,其中脑刺激治疗、神经调节和专科治疗业务均实现中单位数增长[10] 糖尿病业务 - 整体收入同比增长10.9%,其中美国市场实现两位数增长,得益于MiniMed 780G系统的持续推出[11] - 非美国发达市场实现高单位数增长,受益于MiniMed 780G系统的持续采用和CGM使用率的提高[11] 财务指标 - 毛利率同比下降56个基点至64.6%[12] - 研发费用同比增长5.5%至6.75亿美元,销售及管理费用同比增长5.7%至27.7亿美元[13] - 调整后营业利润率同比下降251个基点至24.5%[14] 其他 - 公司宣布将从2025财年第一季度开始将季度现金股利提高至0.70美元,年度股利为2.80美元[14] - 公司预计2025财年有机收入增长4-5%,全年调整后每股收益将在5.40-5.50美元之间[17][18]

A 27x earnings valuation and single-digit growth rate means Medtronic stock is probably going down.Medtronic (MDT -3.43%) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.Heading into earnings, analysts had the medical devices company pegged for a $1.45 per-share profit, but Medtronic "beat" by a penny, reporting $1.46 instead. Similarly, Medtronic exceeded expectations for $8.4 billion in sales by reporting $8.6 billion.And yet t ...

Medtronic (MDT) reported $8.59 billion in revenue for the quarter ended April 2024, representing a year-over-year increase of 0.5%. EPS of $1.46 for the same period compares to $1.57 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.44 billion, representing a surprise of +1.80%. The company delivered an EPS surprise of +0.69%, with the consensus EPS estimate being $1.45.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Medtronic (MDT) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.69%. A quarter ago, it was expected that this medical device company would post earnings of $1.26 per share when it actually produced earnings of $1.30, delivering a surprise of 3.17%.Over the last four quarters, the co ...